C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

DISHMAN CARBOGEN AMCIS announces that its subsidiary, CARBOGEN AMCIS AG has entered into a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

Thursday, April 29, 2021

The companys subsidiary Carbogen Amcis AG a pharmaceutical process development and Active Pharmaceutical Ingredient API and drug products manufacturing company announced today a joint funding agreement with a longstanding Japan based customer to buil...

Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials

Thursday, April 29, 2021

Agilex Biolabs Australias largest and most technologically advanced specialist bioanalytical laboratory for clinical trials and BS Life Sciences a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of...

Hikma announces US FDA approval of KLOXXADO TM (naloxone hydrochloride) nasal spray 8mg

Thursday, April 29, 2021

Hikma Pharmaceuticals PLC Hikma the multinational pharmaceutical company announces the approval of KLOXXADOTM naloxone hydrochloride nasal spray mg by the US Food and Drug Administration FDA for the emergency treatment of known or suspected opioid ov...

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

Thursday, April 29, 2021

Atea Pharmaceuticals Inc a clinicalstage biopharmaceutical company today announced that the first patient has been dosed in the Phase MORNINGSKY trial a global multicenter trial evaluating AT in mild or moderate COVID patients in an outpatient setti...

Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech

Thursday, April 29, 2021

Core One Labs Inc a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market is pleased to announce that it has entered into a definitive share purchase agreement

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne

Thursday, April 29, 2021

Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd today announced its launch of the first available mg mg mg mg mg and mg strength generic version of Absorica isotretinoin capsules

Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region

Friday, April 30, 2021

Melinta Therapeutics Melinta and Hikma Pharmaceuticals PLC Hikma announced they have entered into an exclusive licensing agreement for Vabomere meropenem and vaborbactam and Orbactiv oritavancin two novel antiinfective injectable products for the Mid...

Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

Friday, April 30, 2021

Adcendo a biotech company developing antibodydrug conjugates ADCs for the treatment of cancers announced the successful closing of a EUR million US million Series A financing The investment was led by Novo Seeds the earlystage investment and compan...

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Wednesday, April 28, 2021

Akari Therapeutics Plc a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated

Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA

Wednesday, April 28, 2021

Protalix BioTherapeutics Inc a biopharmaceutical company focused on the development production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cellbased protein expression system